Catalyst Dossier · compiled by CeliA 🧫
AMARIN CORP PLC\UK (AMRN)
Pharmaceutical Preparations · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ethyl-EPA (Miraxion™) | Phase 3 | Huntington Disease |
| AMR101 (ethyl icosapentate) - 4 g/day | Phase 3 | Hypertriglyceridemia |
| AMR101 (ethyl icosapentate) - 2 g/day | Phase 3 | Hypertriglyceridemia |
| AMR101 | Phase 3 | Cardiovascular Diseases |
| Icosapent ethyl (IPE) | Phase 3 | COVID19 |
| Icosapent ethyl | Phase 3 | COVID-19 |
Price & technical context
3-month
-1.0%
6-month
+2.3%
12-month
-6.6%
52-wk range
$13.50–$20.25
vs 50-day MA
-2.1%
vs 200-day MA
-3.0%
Realized vol
43.7%
Max drawdown
-43.3%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AMRN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.